Trial · NCT00108745
Results by group105
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 105
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Arm I (Paclitaxel Poliglumex) | 60.0 | 95% Confidence Interval 51.7 to 68.6 | Months | |
| Overall Survival | Arm II (Paclitaxel) | 56.8 | 95% Confidence Interval 47.3 to 65.9 | Months | |
| Overall Survival | Arm III (Observation) | 58.3 | 95% Confidence Interval 51.9 to 72.5 | Months | |
| Progression-free Survival | Arm I (Paclitaxel Poliglumex) | 16.3 | 95% Confidence Interval 14.4 to 18.9 | Months | |
| Progression-free Survival | Arm II (Paclitaxel) | 18.9 | 95% Confidence Interval 17.0 to 21.8 | Months | |
| Progression-free Survival | Arm III (Observation) | 13.4 | 95% Confidence Interval 11.2 to 15.7 | Months | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm I (Paclitaxel Poliglumex) | Allergic Reaction / Hypersensitivity | 4 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm II (Paclitaxel) | Allergic Reaction / Hypersensitivity | 0 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm III (Observation) | Allergic Reaction / Hypersensitivity | 0 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm I (Paclitaxel Poliglumex) | Dehydration | 4 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm II (Paclitaxel) | Dehydration | 1 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm III (Observation) | Dehydration | 1 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm I (Paclitaxel Poliglumex) | Diarrhea | 7 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm II (Paclitaxel) | Diarrhea | 3 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm III (Observation) | Diarrhea | 2 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm I (Paclitaxel Poliglumex) | Dyspnea | 2 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm II (Paclitaxel) | Dyspnea | 4 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm III (Observation) | Dyspnea | 2 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm I (Paclitaxel Poliglumex) | Fatigue | 6 | participants | |
| Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0 | Arm II (Paclitaxel) | Fatigue | 13 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00108745/results